雷雪萍，博士，硕士研究生导师。2012-2018年在暨南大学药学院攻读博士学位，师从张冬梅研究员与叶文才教授。2018年11月加入广州医科大学药学院分子与临床药理研究所。目前，主要研究方向为肺癌的表观遗传药理学并寻找相应的表观遗传药物，主持广东省省、市级项目5项。近五年来以第一作者或者通讯作者在Cell Death & Disease、Cancer Letters、Theranostics、Journal of Clinical Investigation、American Journal of Cancer Research、Materials Science & Engineering C和Journal of Nanobiotechnology等国际知名期刊发表论文多篇，指导学生获得广东省大学生科研创新项目。兼任中国抗癌协会专业委员会青年委员、广东省肿瘤药理专业委员会委员、广东省实验医学专委会委员、广东省药物筛选与评价专业委员会委员，Plant Medical、Journal of oncology、《上海中医药大学学报》等国内外杂志审稿人。
【联系邮箱】xuepinglei@foxmail.com

【研究方向】 肺癌的表观遗传药理学及相应的表观遗传药物的开发
【主要科研项目】
(1) 广东省自然，青年基金，2019A，Gli1介导的肿瘤细胞外泌体促进非小细胞肺癌血管新生的作用与机制研究，2020-01至2022-12，10万元，在研，主持
(2) 广州市科技厅，基础研究计划基础与应用基础研究项目，6，Gli1经由Snail促进非小细胞肺癌的上皮间充质转换和转移的作用与机制研究， 2020-04至2023-03，20万元，在研，主持
(3) 广东省健康卫生委员会，A**，扁蒴藤素经由 Hh/Gli-1 信号通路抑制肺癌血管新生的作用与机制研究，2020-07至2022-06，0.5万元，在研，主持
(4) 广东省中医药局，面上项目，**，扁蒴藤素经由miR-210抑制肺癌血管新生的作用与机制研究，2020-01至2021-12，1万元，在研，主持
(5) 广州医科大学附属第六医院，一般项目，202011-306，Gli1-CCL2 信号轴介导的转移相关巨噬细胞招募促进非小细胞肺癌肝转移的作用与机制研究，2020-12至2022-11，20万元，主持
【主要论文及著作（代表性）】
(1) Xueping Lei^#, Yihang Zhong^#, Lijuan Huang, Songpei Li, Jijun Fu, Lingmin Zhang, Yu Zhang, Qiudi Deng^*, Xiyong Yu^*. Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer. Cell death & disease, 2020, 11(4):232.
(2) Jijun Fu^#, Chuwen Li^#, Yang Liu^#, Mingyue Chen, Qiang Zhang, Xiyong Yu, Bo Wu, Jiexia Li, Lingran Du, Yuanye Dang, Dan Wu, Minyan Wei^*. Zhiqiang Lin^*, Xueping Lei^*. The microneedles carrying cisplatin and IR820 to perform synergistic chemo-photodynamic therapy against breast cancer. J Nanobiotechnology, 2020, 19; 18(1):146.
(3) Xueping Lei^#, Minfeng Chen^#, Xiaobo Li, Maohua Huang, Qiulin Nie, Nan Ma, Heru Chen, Nanhui Xu; Wencai Ye^*, Dongmei Zhang^*. A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype. Cancer Letters, 2018, 418:239-249.
(4) Xueping Lei^#, Mingfeng Chen^#, Maohua Huang, Xiaobo Li, Changzheng Shi, Dong Zhang, Liangping Luo, Youwei Zhang, Nan Ma, Heru Chen, Huafeng Liang, Wencai Ye^*, Dongmei Zhang^*. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization. Theranostics, 2018, 8(2): 384-398.
(5) Minfeng Chen^#, Xueping Lei^#, Changzheng, Maohua Huang, Xiaobo Li, Baojian Wu, Zhengqiu Li, Weili Han, Bin Du, Jianyang Hu, Qiulin Nie, Weiqian Mai, Nan Ma, Nanhui Xu, Xinyi Zhang, Chunlin Fan, Aihua Hong, Minhan Xia, Liangping Luo, Ande Ma, Hongsheng Li, Qiang Yu, Heru Chen^*, Dongmei Zhang^*, Wencai Ye^*. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. Journal of Clinical Investigation, 2017, 127(10):3689-3701.
(6) Minyan Wei^#, Xueping Lei^#, Jingjing Fu^#, Mingyue Chen, Jiexia Li, Xiyong Yu, Yinlei Lin, Jingping Liu, Lingran Du, Xin Li, Yu Zhang, Yingling Miao, Yugang Huang^*, Lu Liang^*, Jijun Fu^*. The use of amphiphilic copolymer in the solid dispersion formulation of nimodipine to inhibit drug crystallization in the release media: Combining nano-drug delivery system with solid preparations. Materials Science & Engineering C, 2020, 111:110836.
(7) Mingyue Chen^#, Zekuan Xiao^#, Xueping Lei^#, Jiexia Li, Xiyong Yu, Jianye Zhang, Guodong Ye, Yujuan Guo, Guangquan Mo, Chuwen Li, Zhang Yu, Lingmin Zhang^*, Zhiqiang Lin^*, Jijun Fu^*. Preparation, characterization and in vitro-in vivo evaluation of bortezomib supermolecular aggregation nanovehicles. Journal of Nanobiotechnology, 2020, 18(1):57.
(8) Jiajun Li^#, Qiaoru Guo^#, Xueping Lei^#, Lingling Zhang, Chaoyue Su, Yun Liu, Wenmin Zhou, Hubiao Chen, Hui Wang, Fenghua Wang, Yanyan Yan, Jianye Zhang*. Pristimerin induce apoptosis and inhibits proliferation,migration in H1299 cells. Journal of cancer, 2020, 11(21): 6348-6355.
(9) Songpei Li^#, Xueping Lei^#, Zekuan Xiao, Wenyi Xia, Chaojin Lin, Xiaomei Fu, Jijun Fu, Lingmin Zhang^*, Yu Xiyong^*. Dihydrotanshinone I Ameliorates Cardiac Hypertrophy in Diabetic Mice Induced by Chronic High-Fat Feeding. Natural Product Communications, 2020, 578X209526.
(10) Xueping Lei^#, Minfeng Chen^#, Qiulin Nie, Jianyang Hu, ZhenJian Zhuo, Yiu Anita, Heru Chen, NanHui Xu, Maohua Huang, Kaihe Ye, Liangliang Bai, Wencai Ye^*, Zhang Dongmei^*. In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways. American Journal of Cancer Research, 2016, 6(4):843-58.